SFDA Grants Orphan Drug Designation to Agamree for Duchenne Muscular Dystrophy

Detected March 27th, 2026

Summary

The Saudi Food and Drug Authority (SFDA) has granted Santhera Pharmaceuticals orphan drug designation for Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD). This designation allows for a dedicated regulatory pathway for serious or rare diseases but does not constitute formal product registration.

View original document View source feed page

What changed

The Saudi Food and Drug Authority (SFDA) has granted Santhera Pharmaceuticals orphan drug designation for its drug Agamree (vamorolone), indicated for Duchenne muscular dystrophy (DMD). This designation is part of the SFDA's Orphan Drug Program, which aims to accelerate access to treatments for rare diseases. It allows the company to submit a marketing authorization dossier through a specialized pathway, but it is not a final product registration.

While this designation signifies promising preliminary results and commitment to addressing unmet medical needs, the final registration decision will be made after a comprehensive technical evaluation. This initiative aligns with Saudi Vision 2030's Health Sector Transformation Program, emphasizing the SFDA's role in facilitating access to critical therapies for rare and chronic conditions.

What to do next

Submit marketing authorization dossier through the dedicated regulatory pathway for rare diseases.
Undergo comprehensive technical evaluation by the SFDA for final registration decision.

Source document (simplified)

The Saudi Food and Drug Authority (SFDA) has granted Santhera Pharmaceuticals orphan drug designation to Agamree (vamorolone), which is indicated for the treatment of patients with Duchenne muscular dystrophy (DMD).

Registration is Subject to Full Scientific Evaluation

The SFDA clarified that designation under the Orphan Drug Program does not constitute formal product registration. Instead, this designation permits the company to submit a marketing authorization dossier through a dedicated regulatory pathway intended for medicines targeting serious or rare diseases that show promising preliminary results.

The final registration decision will be announced at a later stage, following the completion of a comprehensive technical evaluation in accordance with applicable regulations.

SFDA Orphan Drug Program Accelerates Access to Critical Therapies

This approval highlights the SFDA's commitment to enhancing access to treatments for rare and chronic diseases through the Orphan Drug Program, which is a strategic pillar for accelerating the provision of breakthrough therapies and addressing unmet medical needs. This initiative aligns with the objectives of the Health Sector Transformation Program, which aims to enhance the quality of healthcare within the framework of Saudi Vision 2030.

For further information about the Guidance for Orphan Drug Designation, please visit: https://www.sfda.gov.sa/en/regulations/88482

-
-
-